Year: 2011
Type: article
Study design: Observational Study
Abstract: Prostate cancer (PrCa) is the most common non-skin cancer diagnosed among males in developed countries and the second leading cause of cancer mortality, yet little is known regarding its etiology and factors that influence clinical outcome. Genome-wide association studies (GWAS) of PrCa have identified at least 30 distinct loci associated with small differences in risk. We conducted a GWAS in 2782 advanced PrCa cases (Gleason grade ≥ 8 or tumor stage C/D) and 4458 controls with 571 243 single nucleotide polymorphisms (SNPs). Based on in silico replication of 4679 SNPs (Stage 1, P < 0.02) in two published GWAS with 7358 PrCa cases and 6732 controls, we identified a new susceptibility locus associated with overall PrCa risk at 2q37.3 (rs2292884, P= 4.3 × 10(-8)). We also confirmed a locus suggested by an earlier GWAS at 12q13 (rs902774, P= 8.6 × 10(-9)). The estimated per-allele odds ratios for these loci (1.14 for rs2292884 and 1.17 for rs902774) did not differ between advanced and non-advanced PrCa (case-only test for heterogeneity P= 0.72 and P= 0.61, respectively). Further studies will be needed to assess whether these or other loci are differentially associated with PrCa subtypes.
Source: Human Molecular Genetics
DOI: 10.1093/hmg/ddr295
Authors: Fredrick R. Schumacher, Sonja I. Berndt, Afshan Siddiq, Kevin B. Jacobs, Zhaoming Wang, Sara Lindstrom, Victoria L. Stevens, Constance Chen, Alison M. Mondul, Ruth C. Travis, Daniel O. Stram, Rosalind A. Eeles, Douglas F. Easton, Graham Giles, John L. Hopper, David E. Neal, Freddie C. Hamdy, Jenny L. Donovan, Kenneth Muir, Ali Amin Al Olama, Zsofia Kote-Jarai, Michelle Guy, Gianluca Severi, Henrik Grönberg, William B. Isaacs, Robert Karlsson, Fredrik Wiklund, Jianfeng Xu, Naomi E. Allen, Gerald L. Andriole, Aurelio Barricarte, Heiner Boeing, H. Bas Bueno-de-Mesquita, E. David Crawford, W. Ryan Diver, Carlos A. Gonzalez, J. Michael Gaziano, Edward L. Giovannucci, Mattias Johansson, Loic Le Marchand, Jing Ma, Sabina Sieri, Pär Stattin, Meir J. Stampfer, Anne Tjonneland, Paolo Vineis, Jarmo Virtamo, Ulla Vogel, Stephanie J. Weinstein, Meredith Yeager, Michael J. Thun, Laurence N. Kolonel, Brian E. Henderson, Demetrius Albanes, Richard B. Hayes, Heather Spencer Feigelson, Elio Riboli, David J. Hunter, Stephen J. Chanock, Christopher A. Haiman, Peter Kraft
Institutions: University of Southern California, National Cancer Institute, Division of Cancer Epidemiology and Genetics, Science Applications International Corporation (United States), American Cancer Society, Institute of Cancer Research, University of Cambridge, Cancer Council Victoria, The University of Melbourne, University of Oxford, University of Bristol, University of Warwick, Karolinska Institutet, Johns Hopkins University, Johns Hopkins Medicine, Wake Forest University Health Sciences, Wake Forest University, Washington University in St. Louis, Instituto de Salud Pública de Navarra, German Institute of Human Nutrition, National Institute for Public Health and the Environment, University of Colorado Anschutz, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Harvard University, VA Boston Healthcare System, Centre international de recherche sur le cancer, Umeå University, University of Hawaiʻi at Mānoa, University of Hawaii System, Brigham and Women's Hospital, Fondazione IRCCS Istituto Nazionale dei Tumori, Danish Cancer Society, Imperial College London, Finnish Institute for Health and Welfare, National Research Centre for the Working Environment, Technical University of Denmark, NYU Langone Health, Kaiser Permanente
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: bronze
Funders: Cancer Research Institute, National Cancer Research Institute, Petrus och Augusta Hedlunds Stiftelse, Royal Marsden NHS Foundation Trust, Swedish Cancer Foundation, Cancer Research UK, National Institute for Health and Care Research, Stockholms Läns Landsting, Vetenskapsrådet, National Institutes of Health, Medical Research Council, Health Technology Assessment Programme, National Health and Medical Research Council, Cancer Council Victoria, Cancer Council Queensland, Biomedical Research Council, National Cancer Institute
Awards: G1148307873, G1194619348, NIHR Senior Investigator Award, G1516858932, G188264227, G2296695174, G236237718, G268454541, G2734198957, G2745390170, NIHR Senior Investigator Award, G2993358891, G3437244150, G3503022892, Characterizing Genetic Susceptibility to Breast and Prostate Cancer: The BPC3., G3575964969, G3729156826, Elucidating Loci Involved in Prostate Cancer Suceptibility, G395156118, G4063614301, G4167275758, G4197410787, Kallikrein Gene Variants in Prostate Cancer, G4345139362, G4395940750, G4662672464, G4702869972, Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3, G5101912108, G5272917877, Physicians' Health Study II: Prevention Trial of Vitamins, G5583696067, G5759545421, The ProtecT trial - evaluating the effectiveness of treatments for clinically localised prostate cancer, G5850682332, G5865683244, G589878898, Genetic Susceptibility for Prostate Cancer Progression, G6229591247, G6279653796, G6294906247, G639206035, Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3, PLATYPUSES, Hormonal markers and prostate cancer risk, Epidemiology of Chronic Disease, Health Interventions and DNA Studies, G6858204494, G7242219286, G728243498, G7356264847, Characterizing Genetic Susceptibility to Breast and Prostate Cancer; the BPC3, G7383316951, G7400227903, G758566463, G7664416057, G8123808567, Genetics Variants in the Genome Predisposing to Aggressive PCa, G8818365897, G9000048109, G901453306
OpenAlex ID: W2148783825